【摘要】 目的：观察扶阳化阴方加减治疗原发性肝癌（HCC）的临床疗效。方法：采用掷币法将91例HCC患者分为对照组（45例）与观察组（46例）。对照组给予肝动脉化疗栓塞术（TACE）治疗，观察组在对照组基础上加用扶阳化阴方加减治疗。比较2组治疗前后肝功能指标[谷丙转氨酶（ALT）、谷草转氨酶（AST）、总胆红素（TB）]、血管增生因子指标[血管内皮生长因子（VEGF）、转化生长因子-β1(TGF-β1)]、肿瘤标志物指标[甲胎蛋白（AFP）、甲胎蛋白异质体（AFP-L3）比率、高尔基体蛋白73 (GP73)]及中医证候积分，并评估2组临床疗效及不良反应发生情况。结果：治疗后，观察组总缓解率80.43%，高于对照组60.00%(P<0.05)。治疗后，2组GP73、AFP及AFP-L3比率均较治疗前降低（P<0.05），且观察组治疗后GP73、AFP水平及AFP-L3比率低于对照组（P<0.05）。治疗后，2组AST、ALT及TB均较治疗前降低（P<0.05），且观察组治疗后肝功能指标低于对照组（P<0.05）。治疗后，2组VEGF、TGF-β1及中医证候积分均较治疗前明显降低（P<0.05），且观察组治疗后血管增生因子指标及中医证候积分均低于对照组（P<0.05）。2组不良反应发生率比较，差异无统计学意义（P>0.05）。结论：扶阳化阴方加减治疗HCC效果显著，能有效改善患者肝功能，降低血管增生因子及肿瘤标志物水平，安全性较高。更多还原

【Abstract】 Objective: To observe the clinical effect of modified Fuyang Huayin Prescription on hepatocellular carcinoma(HCC). Methods: A total of 91 patients with HCC were divided into the control group and the observation group according to the coin tossing method,with 45 and 46 cases in each group respectively. The control group was given transarterial chemoembolization(TACE) for treatment,and the observation group was additionally treated with modified Fuyang Huayin Prescription based on the treatment of the control group. Before and after treatment,the indexes of liver function,including alanine aminotransferase(ALT), aspartate aminotransferase(AST), and total bilirubin(TB), the indexes of angiogenic factors, including vascular endothelial growth factor(VEGF) and transforming growth factor-β1(TGF-β1), the indexes of tumor markers, including alpha fetoprotein(AFP), alpha fetoproteinheteroplasmon ratio(AFP-L3) and golgin protein 73(GP73), and traditional Chinese medicine(TCM)syndrome scores were compared between the two groups. The clinical effects and incidence of adverse reactions in the two groups were also evaluated. Results:After treatment,the total remission rate was80.43% in the observation group, higher than that of 60.00% in the control group(P<0.05). After treatment,the levels of GP73,AFP and AFP-L3 ratio in the two groups were decreased when compared with those before treatment(P<0.05),and the above three levels in the observation group were lower than those in the control group(P<0.05). After treatment, the AST, ALT and TB in the two groups were decreased when compared with those before treatment(P<0.05),and the indexes of liver function in the observation group were lower than those in the control group(P<0.05). After treatment,the VEGF,TGF-β1and TCM syndrome scores in both groups were significantly decreased when compared with those before treatment(P<0.05), and the indexes of angiogenic factors and the TCM syndrome scores in the observation group were lower than those in the control group(P<0.05). There was no significant difference being found in the comparison of incidence of adverse reactions in both groups(P>0.05). Conclusion:Modified Fuyang Huayin Prescription has a significant curative effect on patients with advanced hepatocellular carcinoma, which can effectively improve the liver function of patients and decrease the levels of angiogenic factors and tumor markers,with better safety.更多还原